Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abbruzzese JL, Abbruzzese MC, Hess KR et al (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12:1272–1280
Bochtler T, Endris V, Leichsenring J et al (2019) Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. Int J Cancer 145:2963–2973
Bochtler T, Loffler H, Kramer A (2018) Diagnosis and management of metastatic neoplasms with unknown primary. Semin Diagn Pathol 35:199–206
Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death‑1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175
Buchanan CL, Morris EA, Dorn PL et al (2005) Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 12:1045–1053
Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34
Conley BA, Chen AP, O’dwyer PJ et al (2016) NCI-MATCH (molecular analysis for therapy choice)—a national signal finding trial. J Clin Oncol 34:TPS2606
Culine S, Kramar A, Saghatchian M et al (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679–4683
Ettinger DS, Agulnik M, Cates JM et al (2011) NCCN clinical practice guidelines occult primary. J Natl Compr Canc Netw 9:1358–1395
Fizazi K, Greco FA, Pavlidis N et al (2015) Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(5):v133–138
Golfinopoulos V, Pentheroudakis G, Salanti G et al (2009) Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev 35:570–573
Goodman AM, Kato S, Bazhenova L et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16:2598–2608
Groschel S, Bommer M, Hutter B et al (2016) Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud 2:a1180
Gross-Goupil M, Fourcade A, Blot E et al (2012) Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer 48:721–727
Hainsworth JD, Daugaard G, Lesimple T et al (2015) Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: a randomized, phase 2 trial. Cancer 121:1654–1661
Hainsworth JD, Spigel DR, Clark BL et al (2010) Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon oncology research consortium trial. Cancer J 16:70–75
Hainsworth JD, Spigel DR, Thompson DS et al (2009) Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 14:1189–1197
Hayashi H, Kurata T, Takiguchi Y et al (2019) Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol 37:570–579
Hemminki K, Forsti A, Sundquist K et al (2016) Cancer of unknown primary is associated with diabetes. Eur J Cancer Prev 25:246–251
Hemminki K, Ji J, Sundquist J et al (2011) Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol 29:435–440
Hemminki K, Riihimaki M, Sundquist K et al (2013) Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer 133:182–189
Huebner G, Link H, Kohne CH et al (2009) Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 100:44–49
Jones W, Allardice G, Scott I et al (2017) Cancers of unknown primary diagnosed during hospitalization: a population-based study. BMC Cancer 17:85
Kaaks R, Sookthai D, Hemminki K et al (2014) Risk factors for cancers of unknown primary site: results from the prospective EPIC cohort. Int J Cancer 135:2475–2481
Kandalaft PL, Gown AM (2016) Practical applications in immunohistochemistry: carcinomas of unknown primary site. Arch Pathol Lab Med 140:508–523
Krämer A, Stein A, Huebner G et al (2019) Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): results of a multi-center randomized phase II AIO trial. J Clin Oncol 37:4120–4120
Le Tourneau C, Delord JP, Goncalves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324–1334
Lee JR, Kim JS, Roh JL et al (2015) Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study. Radiology 274:764–771
Loffler H, Neben K, Kramer A (2014) Cancer of unknown primary. Epidemiology and pathogenesis. Radiologe 54:107–111
Loffler H, Pfarr N, Kriegsmann M et al (2016) Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget 7:44322–44329
Long GV, Atkinson V, Cebon JS et al (2017) Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol 18:1202–1210
Losa F, Iglesias L, Pane M et al (2018) 2018 consensus statement by the Spanish society of pathology and the Spanish society of medical oncology on the diagnosis and treatment of cancer of unknown primary. Clin Transl Oncol 20:1361–1372
Massard C, Michiels S, Ferte C et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 7:586–595
Pentheroudakis G, Golfinopoulos V, Pavlidis N (2007) Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 43:2026–2036
Petrakis D, Pentheroudakis G, Voulgaris E et al (2013) Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature. Cancer Treat Rev 39:701–708
Randen M, Rutqvist LE, Johansson H (2009) Cancer patients without a known primary: incidence and survival trends in Sweden 1960–2007. Acta Oncol 48:915–920
Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
Ross JS, Wang K, Gay L et al (2015) Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol 1:40–49
Sekine T, Barbosa FG, Sah BR et al (2017) PET/MR outperforms PET/CT in suspected occult tumors. Clin Nucl Med 42:e88–e95
Stelow EB, Yaziji H (2018) Immunohistochemistry, carcinomas of unknown primary, and incidence rates. Semin Diagn Pathol 35:143–152
Wagland R, Bracher M, Drosdowsky A et al (2017) Differences in experiences of care between patients diagnosed with metastatic cancer of known and unknown primaries: mixed-method findings from the 2013 cancer patient experience survey in England. BMJ Open 7:e17881
Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356